For nearly half of all breast cancer patients – those with low levels of the HER2 protein – targeted treatment options have always been limited. Palliative chemo has been the standard of care in stage 4 metastatic patients – until now. In this episode, Dr. Diane Reidy-Lagunes talks with Dr. Shanu Modi, the lead researcher of a groundbreaking MSK trial that proved a drug that combines an antibody with a chemotherapy – trastuzumab deruxtecan (T-DXd) – can control cancer cells and extend survival in stage 4 HER2-low breast cancer patients. With a fresh FDA approval, T-DXd is now being tested on other cancers and changing the way oncologists treat their patients.

See omnystudio.com/listener for privacy information.